RxDoctor Payments DataLook up a doctor →

Saifullah Nasir, MD

Internal Medicine · Schaumburg, ILNPI 1427343938

Payments from drug & device makers

$1,482,526in general payments, 2019–2025

Across 520 payments — averaging $2851.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$770K
  • AbbVie$578K
  • Boehringer Ingelheim International GmbH$45K
  • Amgen$31K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$22K
  • Ionis Pharmaceuticals, Inc.$19K
  • plus $17K from 32 others
$216,733in research payments, 2019–2025

Across 2 payments — averaging $108,367 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$217K

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$7,039100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,482,526 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$355,904
Medicare patients
1,040
Services billed
3,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban311$437,403
XareltoRivaroxaban104$152,447
JardianceEmpagliflozin87$135,143
EntrestoSacubitril/Valsartan63$91,905
OzempicSemaglutide33$55,892
FarxigaDapagliflozin Propanediol38$51,387
JanuviaSitagliptin Phosphate13$19,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,566
Metoprolol Succinate517$8,685
Atorvastatin Calcium829$8,435
Breo ElliptaFluticasone/Vilanterol11$5,311
Potassium Chloride216$4,439
Albuterol Sulfate HfaAlbuterol Sulfate78$4,393
Lisinopril398$3,640
Levothyroxine Sodium195$3,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$958$437,403311 claims
Johnson & JohnsonXarelto$337$152,447104 claims
Boehringer IngelheimJardiance$1,239$135,14387 claims
NovartisEntresto$12,325$91,90563 claims
Novo NordiskOzempic$145$55,89233 claims
AstraZenecaFarxiga$461$51,38738 claims
MerckJanuvia$69$19,58413 claims
GSKTrelegy Ellipta, Breo Ellipta$38$16,87728 claims
AbbVieSynthroid$578,467$1,19913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Schaumburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →